Grant List
Represents Grant table in the DB
GET /v1/grants?sort=-other_investigators
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-other_investigators", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-other_investigators", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=2&sort=-other_investigators", "prev": null }, "data": [ { "type": "Grant", "id": "15990", "attributes": { "award_id": "1R01AI191459-01A1", "title": "Living Microrobot for Active Therapeutic Delivery to Treat Severe Pulmonary Infections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44442, "first_name": "MEENU MISHRA", "last_name": "UPADHYAY", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-02-02", "end_date": "2031-01-31", "award_amount": 720035, "principal_investigator": { "id": 27606, "first_name": "Victor", "last_name": "Nizet", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 27607, "first_name": "Liangfang", "last_name": "Zhang", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44443, "first_name": "JOSEPH", "last_name": "WANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2637, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN DIEGO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Multidrug-resistant (MDR) lower respiratory tract infections represent the single leading cause of infectious disease-associated mortality in the United States. Particularly worrisome trends are being observed in the case of ventilator-associated pneumonia (VAP), which affects vulnerable patient populations in intensive care units (ICUs). Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus (MRSA) are the most common causative agents in global epidemiology of VAP, and they are becoming increasingly prevalent as antibiotics continue to be used indiscriminately and with waning effectiveness. It is imperative that more effective treatment modalities be advanced to adequately manage serious pulmonary infections in the clinical setting. Here we describe a highly innovative delivery and therapeutic concept, living microrobot therapeutics, for critically ill patients with severe P. aeruginosa and MRSA lung infections. The microrobot platform is consisting of Chlamydomonas reinhardtii microalgae modified with neutrophil membrane-coated and drug-loaded polymeric nanoparticles (denoted ‘algae-NP-robots’), and has unique multifold mechanisms of action. The microalgae help to improve tissue penetration and retention of the drug payload within the lungs, while the neutrophil membrane- coated nanoparticles help to shield the drug payload from biological environments, reduce immune clearance, and enable specific binding with target pathogens. Besides carrying drug payload, the neutrophil membrane- coated nanoparticles can further serve as ‘nanosponges’ that act to neutralize excessive pro-inflammatory cytokines, thus reducing the danger of cytokine storm. By combining the unique properties of these two systems, the algae-NP-robots have proven to be a capable platform for active drug delivery and excel at treating bacterial pulmonary infections. In this proposal, we describe our extensive prior published and preliminary results that strongly support the novel therapeutic concept of algae-NP-robots for the treatment of severe Gram-negative and Gram-positive pulmonary bacterial infections in ICU patients. In Aim 1, we will focus on further optimizing the algae-NP-robot formulation to maximize its therapeutic potential. In Aim 2, we seek to better understand the mechanisms by which drug-loaded algae-NP-robots can effectively clear bacterial infection using P. aeruginosa lung infection model, in which efficacy has already been demonstrated. In Aim 3, we will extend the algae-NP- robot platform for the treatment of Gram-positive pathogen (MRSA) lung infection in order to demonstrate the generalizability of the platform. Each of the Aims can be completed independently, although the information gleaned from one can be used to improve the overall approach, which can then benefit the others.", "keywords": [ "Active Biological Transport", "Acute", "Aerosols", "Affect", "Algae", "Antibiotics", "Antimicrobial Resistance", "Attention", "Automobile Driving", "Bacteria", "Bacterial Infections", "Benchmarking", "Binding", "Biological", "Biomimetics", "Blood Platelets", "Cell membrane", "Cells", "Chlamydomonas reinhardtii", "Chronic", "Clinical", "Clinical Management", "Communicable Diseases", "Complex", "Critical Illness", "Data", "Development", "Disease", "Drug Delivery Systems", "Effectiveness", "Encapsulated", "Environment", "Epidemiology", "Formulation", "Glean", "Goals", "In Vitro", "Inflammatory", "Inhalation", "Inherited", "Intensive Care Units", "Intervention", "Location", "Lower Respiratory Tract Infection", "Lower respiratory tract structure", "Lung", "Lung infections", "Medical", "Medicine", "Membrane", "Methods", "Microbial Biofilms", "Modality", "Modeling", "Motion", "Multi-Drug Resistance", "Nebulizer", "Pathologic", "Patients", "Penetration", "Pharmaceutical Preparations", "Property", "Proteins", "Pseudomonas aeruginosa", "Publishing", "Robot", "Route", "Safety", "Source", "Staphylococcus aureus infection", "Structure", "Structure of parenchyma of lung", "System", "Testing", "Therapeutic", "Tissues", "Toxic effect", "Toxin", "Treatment Efficacy", "United States", "Vancomycin", "absorption", "bactericide", "clinical translation", "combat", "comorbidity", "cytokine", "cytokine release syndrome", "design", "effective therapy", "efficacy testing", "fabrication", "immune clearance", "improved", "in vivo", "in vivo evaluation", "innovation", "lung pathogen", "methicillin resistant Staphylococcus aureus", "microrobot", "mortality", "mouse model", "nanomedicine", "nanoparticle", "nanopolymer", "neutrophil", "novel therapeutics", "particle", "pathogen", "patient population", "pulmonary", "success", "trend", "ventilator-associated pneumonia" ], "approved": true } }, { "type": "Grant", "id": "15976", "attributes": { "award_id": "1R21AI190571-01A1", "title": "Statistical Methods for Assessing Immune Correlates of Risk and Protection Using Flexible Two-Phase Sampling Designs that Enrich Longitudinal Samples", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32873, "first_name": "MISRAK", "last_name": "GEZMU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-02-09", "end_date": "2028-01-31", "award_amount": 220000, "principal_investigator": { "id": 44430, "first_name": "Youyi", "last_name": "Fong", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44431, "first_name": "Ying", "last_name": "Huang", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2062, "ror": "", "name": "FRED HUTCHINSON CANCER CENTER", "address": "", "city": "", "state": "WA", "zip": "", "country": "United States", "approved": true }, "abstract": "Immune correlates of protection (CoP) are biomarkers that predict vaccine-induced protection against dis- eases and play a crucial role in the design and development of effective vaccines. The U.S. government (USG)-led initiative to identify CoPs for COVID vaccines highlighted the importance of neutralizing antibody titers as surrogate endpoints, significantly impacting vaccine recommendations and approvals. To effec- tively measure these immune biomarkers, researchers utilize two-phase designs, such as case-cohort or case-control studies, to boost statistical power and enhance representation. This proposal aims to develop novel two-phase sampling designs that allow enrichment of longitudinal immune response marker mea- surements in immune correlates studies. The proposal also aims to develop advanced statistical methods for datasets collected under sampling designs that would introduce bias if analyzed using conventional in- verse probability-weighted methods. Aim 1 focuses on the analysis of the immune response biomarkers measured at the peak immunogenicity time point, while Aim 2 delves into the study of the decaying im- mune response biomarkers. The final product will feature a user-friendly software implementation of the proposed methods, along with its application to analyze COVID correlates datasets from past and ongoing USG-sponsored vaccine efficacy trials.", "keywords": [ "Acceleration", "Adult", "Advisory Committees", "Antibodies", "Antibody titer measurement", "Authorization documentation", "COVID-19", "COVID-19 vaccine", "Case/Control Studies", "Child", "Clinical Data", "Communicable Diseases", "Correlation Studies", "Cost Measures", "Data Correlations", "Data Set", "Development", "Disease", "Future", "Government", "Immune", "Immune System Diseases", "Immune response", "Immunologic Markers", "Infection", "Institution", "Length", "Longitudinal Studies", "Measurement", "Measures", "Methodology", "Methods", "Onset of illness", "Participant", "Phase", "Placebos", "Play", "Probability", "RNA vaccine", "Randomized", "Recommendation", "Research", "Research Personnel", "Resources", "Risk", "Role", "Sampling", "Sampling Biases", "Sampling Studies", "Security", "Series", "Statistical Methods", "Structure", "Surrogate Endpoint", "Techniques", "Time", "Vaccination", "Vaccines", "Visit", "Work", "booster vaccine", "case control", "cohort", "design", "disorder prevention", "disorder risk", "efficacy trial", "flexibility", "global health", "immunogenicity", "immunological status", "improved", "innovation", "interest", "meetings", "neutralizing antibody", "novel", "novel vaccines", "participant enrollment", "predictive marker", "programs", "rational design", "response biomarker", "software development", "time to event", "trial enrollment", "user friendly software", "user-friendly", "vaccine development", "vaccine efficacy", "vaccine platform", "vaccine-induced immunity", "vaccinology" ], "approved": true } }, { "type": "Grant", "id": "15975", "attributes": { "award_id": "1R01AI195779-01", "title": "Regulatory T cell memory in human tissues", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44428, "first_name": "CHAO", "last_name": "JIANG", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-02-06", "end_date": "2030-01-31", "award_amount": 3144408, "principal_investigator": { "id": 7597, "first_name": "Donna L.", "last_name": "Farber", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 745, "ror": "", "name": "SCRIPPS RESEARCH INSTITUTE, THE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 44429, "first_name": "Peter Alan", "last_name": "Sims", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "T cell memory is stored across heterogeneous subsets with diverse functions in both tissues and circulation. While most studies have focused on the pro-inflammatory and cytotoxic functions of memory T cells, regulatory T cells (Tregs) serve an equally important immunomodulatory role in memory responses, particularly in tissues. While specific roles for Tregs in establishing tolerance and promoting tissue homeostasis have been elucidated in mouse models, the role of human Tregs in healthy immune responses and protective immunity in vivo has been difficult to assess. Moreover, the identity and function of human Tregs in diverse tissues remains unknown. We have established an organ donor tissue resource for human immunology that has allowed us to profile antigen-specific T cells across human tissues. Through these efforts, we found that antigen-specific Tregs are substantially enriched among memory T cells that respond to antigens from multiple viruses, including SARS-CoV-2, influenza, and EBV, and are particularly enriched in lymph nodes, spleen and lungs compared to blood, bone marrow and other sites. In addition, we found that memory Tregs induce an activation program that is distinct from effector memory T cells (TEM) involving CCL17 as a novel Treg-derived cytokine not produced by TEM cells or any other T cell subset. Moreover, tissue memory Tregs exhibit clonal overlap with TEM cells within and between sites. These findings raise the possibility that memory Tregs are generated along with TEM during priming and that they share a common pre-cursor with TEM. In the proposed studies, we will pursue three aims: 1) Determine the role of antigen and tissue in memory Treg induction; 2) Define the clonal and migratory relationships (i.e. tissue distributions) between memory Treg and other memory subsets; 3) Elucidate the functional and spatial interactions of tissue Tregs with immune and structural cells in the lymph node. We will combine state-of-the-art technologies for single-cell and spatial profiling with our unique human tissue resource to elucidate mechanisms for the generation, function, and maintenance of memory Tregs in human tissues. The results from this study will be important for designing strategies to promote immunoregulation and tissue repair for protective immunity and can inform Treg-directed therapies for autoimmunity and transplantation.", "keywords": [ "2019-nCoV", "Adult", "Affect", "Age", "Allergens", "Antigens", "Autoantigens", "Autocrine Communication", "Autoimmunity", "Blocking Antibodies", "Blood", "Bone Marrow", "CCL17 gene", "CCR8 gene", "COVID-19", "Cell Communication", "Cells", "Cellular Indexing of Transcriptomes and Epitopes by Sequencing", "Chemotaxis", "Circulation", "Cytoprotection", "Drug or chemical Tissue Distribution", "Environment", "Exhibits", "FOXP3 gene", "Fatty acid glycerol esters", "Frequencies", "Gene Expression", "Gene Expression Profile", "Generations", "Homeostasis", "Homing", "Human", "Human Herpesvirus 4", "Human Resources", "IL2RA gene", "Immune", "Immune response", "Immune system", "Immunity", "Immunization", "Immunology", "In Situ", "Individual", "Infection", "Inflammation", "Inflammatory", "Influenza", "Life", "Lung", "Lymphoid Tissue", "Maintenance", "Mediating", "Memory", "Mucous Membrane", "Mus", "Muscle", "Organ Donor", "Pathway interactions", "Phenotype", "Play", "Population", "Proteins", "RNA vaccine", "Regulation", "Regulatory T-Lymphocyte", "Research", "Role", "SARS-CoV-2 infection", "Signal Transduction", "Site", "Slice", "Spleen", "Stromal Cells", "T cell differentiation", "T cell therapy", "T memory cell", "T-Cell Activation", "T-Lymphocyte", "T-Lymphocyte Subsets", "Technology", "Thymus Gland", "Tissues", "Transplantation", "Vaccines", "Virus", "Virus Diseases", "age related changes", "antigen-specific T cells", "cell motility", "chemokine", "cytokine", "cytotoxic", "design", "human tissue", "immunoregulation", "in vivo", "lymph nodes", "lymphoid organ", "memory CD4 T lymphocyte", "mouse model", "multimodality", "novel", "pathogen", "programs", "receptor", "recruit", "response", "single cell technology", "tissue repair", "tissue resident memory T cell", "tissue resource", "transcription factor", "tumor" ], "approved": true } }, { "type": "Grant", "id": "15974", "attributes": { "award_id": "1R01AI191417-01A1", "title": "MARVELOUS: Maternal RSV Vaccination- Evaluating Optimal Immune Responses", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 44292, "first_name": "MERCY R", "last_name": "PRABHUDAS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-02-06", "end_date": "2030-01-31", "award_amount": 3859259, "principal_investigator": { "id": 21683, "first_name": "Andrea Goldberg", "last_name": "Edlow", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 736, "ror": "https://ror.org/002pd6e78", "name": "Massachusetts General Hospital", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 22942, "first_name": "SABRA L.", "last_name": "KLEIN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 344, "ror": "https://ror.org/00za53h95", "name": "Johns Hopkins University", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, { "id": 44427, "first_name": "Liza", "last_name": "Konnikova", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3427, "ror": "", "name": "MASSACHUSETTS GENERAL HOSPITAL", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "The recent approval of the Respiratory Syncytial Virus (RSV) vaccine for administration in pregnancy presents a novel opportunity to define immune responses of the maternal-fetal dyad, and how that response crosses the placenta and mammary tissue. Recent work indicates that timing of maternal RSV vaccination alters placental antibody transfer to the fetus. To maximize infant protection after maternal RSV vaccination, key gaps in knowledge include: 1. The extent to which maternal vaccination elicits direct fetal antigen-agnostic and antigen- specific cellular responses to augment infant protection from RSV and other infections. 2. How gestational age at vaccination alters maternal antibody response, subsequent placental and breastmilk antibody transfer, and persistence of immunity in the infant. The proposed studies will test the central hypothesis that timing of maternal vaccination, antibody Fc-receptor binding properties, glycosylation profiles, neutralizing antibody levels and non-neutralizing antibody functions are all key determinants of placental and breastmilk antibody transfer to the neonate. These antibody features will work in concert with fetal innate and adaptive immune responses to maternal vaccination, driving protection of the infant through 6 months of age. In a cohort of 400 pregnant women and their infants, this study will examine fetal cellular responses to maternal RSV vaccination, both RSV-agnostic and RSV-specific, by evaluating fetal immune cells isolated from placental villi and cord blood (Aim 1). It will comprehensively profile placentally- and breastmilk-transferred antibodies after RSV vaccination in pregnancy, evaluating IgG subclass, Fc-receptor binding, glycosylation profile, and neutralizing capacity of antibodies using in vivo and in vitro assays (Aim 2). It will then evaluate how antibody properties and timing of maternal vaccination impact the durability of antibody-mediated and cellular immunity in infant blood and breastmilk, through 6 months of age (Aim 3). Machine learning approaches will be used to estimate the magnitude and specific features of protective immune responses induced by maternal vaccination, not only for RSV, but also for influenza, Tdap, and COVID-19. These methods will generate a comprehensive model of durable infant protection from maternal vaccination spanning multiple pathogens. Defining these immune principles across the maternal-fetal dyad will generate key biological insights necessary to optimize neonatal and infant protection.", "keywords": [ "3-Dimensional", "Address", "Age Months", "Antibodies", "Antibody Response", "Antibody-mediated protection", "Antigens", "Automobile Driving", "Biological", "Biological Assay", "Blood", "Breast", "Breast Epithelial Cells", "COVID-19", "COVID-19 vaccination", "COVID-19 vaccine", "Cell Separation", "Cells", "Cellular Immunity", "Characteristics", "Chorionic villi", "Clinical Trials", "Clonal Expansion", "Colostrum", "Data", "Disease", "Ensure", "Fc Receptor", "Fetus", "Future", "Gene Expression Profile", "Gestational Age", "Human Milk", "Immune", "Immune response", "Immune system", "Immunity", "Immunoglobulin G", "In Vitro", "Infant", "Infection", "Influenza", "Innate Immune Response", "Knowledge", "Life", "Longevity", "Machine Learning", "Maternal antibody", "Measures", "Mediating", "Memory", "Methods", "Milk", "Modeling", "Mononuclear", "Mothers", "Nature", "Neonatal", "Peptides", "Pertussis", "Phase III Clinical Trials", "Phenotype", "Placenta", "Plasma", "Polysaccharides", "Pregnancy", "Pregnant Women", "Premature Birth", "Property", "Prospective cohort", "Recommendation", "Respiratory Syncytial Virus Vaccines", "Respiratory syncytial virus", "Serology", "System", "T cell response", "T memory cell", "T-Lymphocyte", "Testing", "Time", "Tissues", "Training", "Umbilical Cord Blood", "Vaccinated", "Vaccination", "Vaccine Design", "Vaccines", "Work", "adaptive immune response", "anti-influenza", "antibody test", "antibody transfer", "cohort", "embryo/fetus antigen", "emerging pathogen", "experimental study", "fetal", "fetal immunity", "glycosylation", "immune function", "in vitro Assay", "in vivo", "infant morbidity", "infant morbidity/mortality", "insight", "large datasets", "machine learning method", "machine learning model", "mammary", "maternal vaccination", "neonatal immunity", "neonate", "neutralizing antibody", "novel", "pathogen", "placental transfer", "predictive modeling", "prenatal exposure", "receptor binding", "respiratory pathogen", "response", "sex", "transcytosis", "unvaccinated", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "15963", "attributes": { "award_id": "1R01AG083894-01A1", "title": "Longitudinal MRI Measures of Cerebrovascular Injury and AD Atrophy in a Study of Latinos (SOL-INCA-MRI Long)", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 44413, "first_name": "MARYAM X", "last_name": "GHALEH", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-03-15", "end_date": "2030-11-30", "award_amount": 3517625, "principal_investigator": { "id": 44414, "first_name": "Charles", "last_name": "DeCarli", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44415, "first_name": "Hector M", "last_name": "Gonzalez", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3418, "ror": "", "name": "UNIVERSITY OF CALIFORNIA AT DAVIS", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Latinos constitute a heterogeneous population which accounted for slightly more than 50% of the United States (US) population growth for 2010 to 2020. Latinos are also becoming a larger proportion of older individuals in the US. Despite this, biomarker studies of normal aging and cognitive impairment remain limited, and the Hispanic Community Health Study/Study of Latinos (HCHS/SOL) constitutes the only known representative sample. Moreover, epidemiological data indicate that Latinos have a higher prevalence of vascular risk factors, lower cardiovascular health metrics, and a greater likelihood of having mild cognitive impairment (MCI) or dementia due non-Alzheimer’s disease processes that differ by heritage. Consequently, diagnosis and treatment of Latino persons with cognitive impairment may be more challenging, but more amenable to prevention through reduction of vascular risk factors than non-Hispanic White persons where vascular risk and disease is less prevalent. The first cycle of “MRI Measures of Cerebrovascular Injury and Alzheimer’s disease Atrophy in a Study of Latinos (RF1 AG054548; AKA SOL-INCA-MRI)” was designed to identify biological underpinnings of normal cognitive aging, MCI and Alzheimer’s disease and related dementias (ADRD) in a representative subgroup of the HCHS/SOL 62 + 9 years of age on average. Despite restrictions imposed by the COVID pandemic, our investigators successfully obtained brain MRI from 2668 individuals or >95% of the proposed study cohort. From these data we have published on 1) differences in brain structure from ages 35-85; 2) the impact of vascular risk and sleep on brain structure; 4) the association of cognition with subsequent MRI measures; and 4) genetic influences on select brain measures. These early results, while of scientific value, are cross- sectional and do not reflect ongoing degeneration or incident vascular injury, limiting inferential power that might extend scientific knowledge of brain aging and ADRD in this unique cohort. For this application, we propose to extend our work to include longitudinal MRI analysis, leveraging longitudinal biomarker and clinical data from 3 visits, spanning approximately 12 years of HCHS/SOL and its cognitive ancillary study (SOL-INCA- AD; R01 AG075758, Gonzalez, DeCarli Co-PIs) on a deeply characterized and diverse Hispanic/Latino cohort. Adding longitudinal image analysis in combination with longitudinal lifestyle, medical risk factors, plasma ATN biomarkers, genetics and cognitive assessment in this Latino cohort will address multiple ADRD research milestones and priorities while enabling stronger statistical inference of risk and resilience factors amongst representative, yet relatively young-old members of diverse Latino communities, creating the opportunity to identify modifiable risk factors, potentially reducing societal burden due to later-life ADRD in this rapidly growing portion of the older US population.", "keywords": [ "9 year old", "Age", "Aging", "Alzheimer's Disease", "Alzheimer's disease related dementia", "Amyloid beta-Protein", "Ancillary Study", "Atrophic", "Biological", "Biological Markers", "Blood Vessels", "Brain", "Brain Injuries", "COVID-19 pandemic", "Cerebrovascular Trauma", "Clinical Data", "Cognition", "Cognitive", "Cognitive aging", "Communities", "Data", "Dementia", "Diagnosis", "Disease", "Funding", "Genetic", "Genetic Risk", "Growth", "Hemorrhage", "High Prevalence", "Hispanic", "Hispanic Community Health Study/Study of Latinos", "Image Analysis", "Impaired cognition", "Individual", "Infarction", "Intercept", "K-Series Research Career Programs", "Knowledge", "Latino", "Latino Population", "Life", "Life Style", "Magnetic Resonance Imaging", "Measures", "Mediating", "Medical", "Nerve Degeneration", "Not Hispanic or Latino", "Older Population", "Participant", "Pathologic", "Persons", "Plasma", "Population", "Population Growth", "Population Heterogeneity", "Prevention", "Process", "Publishing", "Research", "Research Personnel", "Risk", "Risk Factors", "Sampling", "Sleep", "Structure", "Study of Latinos", "Subgroup", "Time", "United States", "United States National Institutes of Health", "Vascular Diseases", "Visit", "Water", "White Matter Hyperintensity", "Work", "aging brain", "brain magnetic resonance imaging", "cardiovascular health", "cerebral microbleeds", "cognitive performance", "cognitive testing", "cohort", "cohort research", "design", "disparity reduction", "endophenotype", "epidemiologic data", "gray matter", "magnetic resonance imaging biomarker", "member", "mild cognitive impairment", "modifiable risk", "morphometry", "normal aging", "resilience factor", "serial imaging", "social culture", "sociocultural determinant", "tau-1", "vascular injury", "vascular risk factor", "white matter" ], "approved": true } }, { "type": "Grant", "id": "15954", "attributes": { "award_id": "1R01AG092810-01A1", "title": "The Impact of Changes in Primary Care Clinicians' Work Effort on the Health of Older Adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 44399, "first_name": "MARCEL", "last_name": "SALIVE", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2031-01-31", "award_amount": 680086, "principal_investigator": { "id": 44400, "first_name": "Bruce E.", "last_name": "Landon", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44401, "first_name": "Lisa", "last_name": "Rotenstein", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 2635, "ror": "", "name": "UNIVERSITY OF CALIFORNIA, SAN FRANCISCO", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "There are demonstrated benefits of comprehensive, continuous, and coordinated primary care for older adults, ranging from higher rates of appropriate preventive care receipt to lower rates of hospitalization and mortality. However, the benefits of strong primary care are threatened by an impending primary care workforce crisis, exacerbated by prevalent trends of primary care physician (PCP) workforce attrition and clinical effort reduction. Partly in response to these trends, there is increasing representation of NPs and PAs, collectively referred to as advanced practice clinicians (APCs), in the primary care workforce. However, burnout, intent to leave, and intent to reduce clinical effort are also prevalent among primary care APCs. These trends across primary care clinicians (PCCs; comprising physicians, NPs, and PAs) may significantly threaten quality of and access to care for older adults. At present, there is limited evidence to inform healthcare leaders and policy makers about how primary care workforce disruptions impact access to and quality of primary care received by older adults. There is additionally insufficient information on the actionable factors associated with PCC turnover and PCC reductions in clinical effort. In this grant, we will leverage data from Medicare fee-for-service and Medicare Advantage, which together provide coverage for 93% of older adults, in order to: 1) quantify the number of Medicare patients impacted by PCC turnover and sustained reductions in billed clinical effort and identify factors associated with these work effort changes; 2) assess the impact of PCC turnover and PCCs’ sustained reductions in billed clinical effort on patterns of primary care receipt and non-primary care utilization, including emergency department visits and hospitalizations; and 3) assess the impact of PCC turnover and sustained reductions in billed clinical effort on quality of care for older adults. All analyses will be conducted for the overall population of older adults as well as for subgroups of more vulnerable older adults, including those with dementia, multiple chronic conditions, and from underserved groups (e.g., dually eligible for Medicaid). Additionally, analyses will be conducted for physicians and APCs separately, and for the overall study period and comparing the pre- and post-COVID periods. The results from this study will elucidate how changes in PCCs’ work patterns influence the care of the growing US population of older adults. They will provide actionable insights for leaders seeking to design clinical systems and policies that enhance primary care for older adults. Overall, this proposal will enhance the ability of clinical, operational, and policy leaders to maintain the effort of the primary care workforce and optimize care for older adults.", "keywords": [ "Accident and Emergency department", "Address", "Affect", "COVID-19 pandemic", "Caring", "Clinical", "Complex", "Continuity of Patient Care", "Counseling", "Data", "Dementia", "Documentation", "Educational process of instructing", "Emergency department visit", "Fee-for-Service Plans", "Grant", "Health", "Health Care", "Health Services Accessibility", "Hospitalization", "Investments", "Left", "Location", "Measures", "Medicaid eligibility", "Medical Students", "Medicare", "Modeling", "Occupations", "Older Population", "Outcome", "Patients", "Pattern", "Physicians", "Policies", "Policy Maker", "Preventive care", "Primary Care", "Primary Care Physician", "Process", "Quality of Care", "Reporting", "Specialist", "Subgroup", "System", "Testing", "Time", "Underserved Population", "United States", "Visit", "Work", "acute care", "beneficiary", "burnout", "care delivery", "care providers", "care systems", "care utilization", "cost", "demographics", "design", "dual eligible", "hospitalization rates", "improved outcome", "insight", "large scale data", "mortality", "multiple chronic conditions", "older adult", "post-COVID-19", "primary care clinician", "response", "screening", "social", "trend" ], "approved": true } }, { "type": "Grant", "id": "15948", "attributes": { "award_id": "1R21AI196828-01", "title": "N Protein Nexus: Rewiring Host Translation Machinery for SARS-CoV-2's Early Replicative Advantage", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32891, "first_name": "MARY KATHERINE BRADFORD", "last_name": "PLIMACK", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2028-03-31", "award_amount": 213048, "principal_investigator": { "id": 23292, "first_name": "Rong", "last_name": "Hai", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1190, "ror": "", "name": "UNIVERSITY OF CALIFORNIA RIVERSIDE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 44391, "first_name": "Sean E", "last_name": "O'Leary", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3407, "ror": "", "name": "UNIVERSITY OF CALIFORNIA RIVERSIDE", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "ABSTRACT: Dependence on host-cell machinery for protein synthesis poses a significant challenge to coronavirus replication, particularly at the onset of infection when viral genomic RNA must compete with an abundance of host mRNAs for translation. To overcome this hurdle, viruses have evolved sophisticated strategies to commandeer the host translation machinery. While multiple mechanisms by which SARS-CoV-2 hijacks host translation have been elucidated, almost all involve non-structural viral proteins. This raises a fundamental question: how does SARS- CoV-2 establish a translational foothold during the early stages of infection, before non-structural proteins are synthesized? The viral nucleocapsid (N) protein is the primary viral factor present at this early stage of infection and has been shown to manipulate cell machinery to facilitate infection. We have found that N protein physically and functionally interacts with the human translation machinery, facilitating preferential viral translation. Moreover, our results suggest that the viral genome's 5ʹ untranslated region exploits high-affinity N protein binding to potentiate selective viral RNA recognition for translation. We hypothesize that N protein is a key mediator of viral translational hijacking in early SARS-CoV-2 infection, establishing a new paradigm within the N- protein functional repertoire. This proposal now seeks to elucidate the molecular mechanisms of host protein- synthesis modulation by N protein for viral benefit during early infection. Through two specific aims, we will (1) identify the viral determinants responsible for the impact of N protein on viral RNA translation and (2) delineate the roles of host factors in N protein viral-translation enhancement. By combining biochemical, biophysical, and genetic approaches, we will establish a comprehensive understanding of unanticipated host-virus interactions that govern SARS-CoV-2 pathogenesis, uncovering novel viral vulnerabilities that can be exploited to develop targeted antiviral therapy. Ultimately, this study will provide new insights for innovative therapeutic strategies that can be extended to other viruses with RNA-binding proteins, offering a promising avenue for smothering infection at its onset. 3", "keywords": [ "2019-nCoV", "Affinity", "Amino Acids", "Anti-viral Therapy", "Binding Proteins", "Biochemical", "Biology", "Biophysics", "COVID-19", "COVID-19 treatment", "Cells", "Communicable Diseases", "Coronavirus", "Dependence", "Elements", "Elongation Factor", "Face", "Genomic approach", "Human", "Infection", "Integration Host Factors", "Knowledge", "Life Cycle Stages", "Maps", "Mediating", "Mediator", "Messenger RNA", "Methods", "Molecular", "Nonstructural Protein", "Nucleocapsid", "Nucleocapsid Proteins", "Peptide Initiation Factors", "Phase", "Preparation", "Protein Biosynthesis", "Proteins", "RNA Viruses", "RNA-Binding Proteins", "RNA-Protein Interaction", "Recombinants", "Ribosomes", "Role", "SARS-CoV-2 genome", "SARS-CoV-2 infection", "SARS-CoV-2 pathogenesis", "Site", "Therapeutic", "Translations", "Untranslated RNA", "Untranslated Regions", "Viral", "Viral Genome", "Viral N Protein", "Viral Nonstructural Proteins", "Viral Proteins", "Virus", "antiviral drug development", "biophysical analysis", "biophysical techniques", "combat", "functional genomics", "genetic analysis", "genetic approach", "genomic RNA", "influenzavirus", "innovation", "insight", "mRNA Translation", "new therapeutic target", "novel", "pathogen", "pathogenic virus", "protein expression", "therapy development", "translational impact", "viral RNA", "viral genomics", "virus host interaction" ], "approved": true } }, { "type": "Grant", "id": "15945", "attributes": { "award_id": "1R21AI191344-01A1", "title": "Peptide-conjugated phosphodiamidate morpholino oligonucleotide (PPMO)-based henipavirus therapeutics", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 32808, "first_name": "MINDY I", "last_name": "DAVIS", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2026-04-01", "end_date": "2028-03-31", "award_amount": 475339, "principal_investigator": { "id": 8360, "first_name": "Christopher F", "last_name": "Basler", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 625, "ror": "https://ror.org/04a9tmd77", "name": "Icahn School of Medicine at Mount Sinai", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 44390, "first_name": "Hong M", "last_name": "Moulton", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 3404, "ror": "", "name": "ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Nipah virus (NiV) is a highly lethal zoonotic paramyxovirus from the Henipavirus genus that causes severe respiratory disease and encephalitis in humans. To date, no antivirals have been approved for treatment or prevention of these infections. We will develop and test peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO)-based compounds as anti-NiV therapeutics. Phosphorodiamidate morpholino oligomers (PMO) are water soluble, nucleic-acid-like antisense agents having nuclease resistance. They form stable duplexes with complementary RNA, affecting function. PMOs are FDA-approved to treat forms of Duchenne muscular dystrophy. PMOs can be conjugated to a cell-penetrating peptide to produce peptide-PMO (PPMO) which enter cells without the need for transfection. Aqueous solutions of PPMOs have shown considerable antiviral efficacy against a number of RNA viruses. We evaluated the anti-henipavirus potential of PPMOs using the non-pathogenic henipavirus Cedar virus (CedV) at BSL2. We designed PPMOs to target the start codons for the mRNAs encoding the three viral proteins essential for viral RNA synthesis- nucleoprotein (N), phosphoprotein (P) and large protein (L). These exhibited low micromolar activity versus CedV replication in Vero cells. A pilot test of PPMO targeting NiV N and P demonstrated anti-NiV activity in cell culture. That the P gene is a viable target is notable because the NiV P gene also encodes two critical virulence factors, V and W, which disable the type I interferon response. Because V and W share the same N-terminus as the P protein, an inhibitor of P translation will also block V and W expression. Therefore, a single P-targeting PPMO could disable viral RNA synthesis and simultaneously promote antiviral IFN-I responses, potentially enhancing antiviral activity. Building on these data, we will design PPMOs to target NiV N, P and L mRNAs. These will be tested for inhibition against live NiV at BSL4 and mechanism of action assessed by using a BSL2 NiV minigenome assay. We will test the hypotheses that antiviral activity of PPMOs correlates with suppression of translation of the targeted mRNA and determine whether targeting the P start codon will augment PPMO antiviral effects by suppressing expression of V and W. We will then test the best performing PPMO in vivo, using a hamster model. We will use airway administration because (1) Respiratory symptoms are a significant component of NiV infection. (2) In hamsters, infection can spread from the airway to the central nervous system (CNS) via the olfactory bulb. (3) Prior studies have used respiratory delivery and respiratory NiV challenge to test therapeutic candidates. (4) We recently demonstrated that PPMOs delivered directly to the airway at a 1 mg/kg dose reduced SARS-CoV-2 lung titers by >104 infectious units per gram lung tissue, and our Preliminary Data demonstrates that intranasal delivery to mice results in sustained PPMO effects throughout the upper airway and extending into the olfactory bulb. The in vivo studies will include assessment of tolerability, tissue distribution and efficacy against NiV of the top performing PPMO. We expect these efforts to yield a candidate PPMO for further development.", "keywords": [ "2019-nCoV", "Address", "Affect", "Animal Model", "Anti-viral Agents", "Anti-viral Therapy", "Antisense Oligonucleotides", "Biological Assay", "Brain", "Cell Culture Techniques", "Cells", "Central Nervous System", "Clinical Trials", "Code", "Complementary RNA", "Conserved Sequence", "Containment", "Data", "Development", "Disease", "Disease Outbreaks", "Dose", "Drug or chemical Tissue Distribution", "Duchenne muscular dystrophy", "Effectiveness", "Encephalitis", "Exhibits", "FDA approved", "Family", "Filovirus", "Gene Expression", "Genes", "Genetic Transcription", "Genome", "Glycine decarboxylase", "Goals", "Hamsters", "Health", "Hendra Virus", "Henipavirus", "Human", "Immune Evasion", "In Vitro", "Infection", "Infection prevention", "Initiator Codon", "Interferon Type I", "Interferons", "Intranasal Administration", "Introns", "Lung", "Malaysia", "Measles virus", "Mesocricetus auratus", "Messenger RNA", "Modeling", "Mus", "Mutate", "Mutation", "National Institute of Allergy and Infectious Disease", "Nipah Virus", "Nose", "Nucleic Acids", "Nucleoproteins", "Oligonucleotides", "Paramyxovirus", "Penetration", "Peptides", "Phosphoproteins", "Productivity", "Proteins", "Public Health", "RNA Splicing", "RNA Viruses", "RNA chemical synthesis", "Reporter", "Resistance", "Respiratory Disease", "Respiratory Signs and Symptoms", "Respiratory syncytial virus", "Rhabdoviridae", "Route", "Singapore", "Site", "Structure of parenchyma of lung", "Testing", "Therapeutic", "Tissues", "Toxic effect", "Transfection", "Transgenes", "Translations", "Treatment Efficacy", "Vaccines", "Vero Cells", "Viral", "Viral Physiology", "Viral Proteins", "Virulence Factors", "Virus", "Virus Diseases", "Virus Replication", "Water", "Work", "World Health Organization", "Zoonoses", "anti-viral efficacy", "aqueous", "data modeling", "design", "effective therapy", "in vivo", "inhibitor", "mRNA Translation", "medical countermeasure", "member", "mouse model", "nuclease", "olfactory bulb", "pandemic potential", "pathogen", "phosphorodiamidate morpholino oligomer", "pilot test", "priority pathogen", "prophylactic", "replicase", "respiratory", "response", "therapeutic candidate", "therapeutic evaluation", "transmission process", "viral RNA" ], "approved": true } }, { "type": "Grant", "id": "15943", "attributes": { "award_id": "1R13OD039737-01", "title": "Annual Symposium on Nonhuman Primates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 44387, "first_name": "SIGE", "last_name": "ZOU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-05-01", "end_date": "2028-04-30", "award_amount": 74999, "principal_investigator": { "id": 8251, "first_name": "Deborah H.", "last_name": "Fuller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44388, "first_name": "Jon E", "last_name": "Levine", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44389, "first_name": "Corinna Nicole", "last_name": "Ross", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "With this R13 application, we request funding to support, in part, the costs for planning, publicizing, and hosting the 42nd, 43rd, and 44th Annual Symposia on Nonhuman Primate Models for AIDS. For more than four decades, this symposium has served as the premier scientific forum for the exchange of information, including new research findings and scientific perspectives, among HIV/AIDS investigators whose research includes studies in nonhuman primates (NHPs). Disseminating the latest research findings in NHP models of AIDS while also facilitating discussion and exchange of information between basic scientists and clinicians remains a priority, as do focusing on emerging technologies to accelerate translation of NHP studies into the clinic and engaging a broader and more diverse group of researchers in HIV/AIDS research in NHP models. This meeting, the only one of its kind in the world, convenes an international group of scientists whose research focuses on the study of natural and experimental immunodeficiency virus infections in NHPs, as well as on the development of novel therapeutics, prophylactic vaccines for HIV, and curative approaches. Emerging topics in related infectious diseases (such as COVID-19 pathogenesis, vaccines and treatment) may also be included. The seven National Primate Research Centers (NPRCs) host this meeting in rotation, and upcoming symposia hosts will be the Wisconsin (2025), Southwest (2026), and Washington (2027) NPRCs. We plan a hybrid format with most participants attending in person and others joining online to access oral and poster sessions. The conference will begin on day 1 with registration, a keynote address by a leading HIV/AIDS researcher, and an evening reception. The following two and a half days will include scientific presentations from invited speakers and accepted oral abstracts. Each symposium scientific committee will select session topics and speakers to highlight new and cutting-edge technologies in their respective fields. Each session will open with a 30-minute talk by an invited chair. Individuals whose abstracts are accepted for oral presentations will give the remaining session talks. A poster session will occur on the evening of day 2, and there will be a banquet on the evening of day 3. As is traditional for this symposium, the Journal of Medical Primatology will publish all poster and oral abstracts in a special issue. In partnership with the HIV Vaccine Trials Network (HVTN), the NHP AIDS Symposium will also host a pre-symposium meeting for early-stage investigators (ESI). This meeting will be open to the attendees of a linked ESI Conference the HVTN sponsors. ESI attendees and mentors will focus on grant writing, budgeting, and networking, and will participate in a Q&A with NIH Program Officers. We believe bringing together researchers from a variety of diverse backgrounds will generate future collaborations and scientific advances. Knowledge shared and gained at upcoming Annual Nonhuman Primate Models for AIDS Symposia will further the continued, effective use of NHP models to maintain long term control of HIV replication in the absence of antiretroviral therapy and to design interventions to prevent or eradicate HIV infection.", "keywords": [ "2019-nCoV", "AIDS Vaccines", "Acceleration", "Acquired Immunodeficiency Syndrome", "Address", "Applications Grants", "Budgets", "COVID-19 pathogenesis", "COVID-19 treatment", "COVID-19 vaccine", "Clinic", "Collaborations", "Communicable Diseases", "Development", "Disease", "Drug Delivery Systems", "Emerging Technologies", "Epidemic", "Fees", "Fostering", "Funding", "Future", "Generations", "Grant", "HIV", "HIV Infections", "HIV Vaccine Trials Network", "HIV vaccine", "HIV/AIDS", "Health", "Human", "Hybrids", "Immune response", "Immunologist", "Individual", "International", "Intervention", "Journals", "Knowledge", "Life", "Link", "Logistics", "Medical", "Mentors", "Mission", "Monkeypox", "Oral", "Participant", "Pathogenesis", "Persons", "Preventive vaccine", "Primates", "Publishing", "Research", "Research Personnel", "Resources", "Rotation", "SIV", "Scientific Advances and Accomplishments", "Scientist", "Technology", "Testing", "Translations", "United States National Institutes of Health", "Universities", "Viral reservoir", "Virus", "Virus Diseases", "Washington", "Wisconsin", "Writing", "Zika Virus", "Zoonoses", "antiretroviral therapy", "cost", "disability", "emerging virus", "experience", "falls", "global health", "immunodeficiency", "innovation", "meetings", "neutralizing antibody", "nonhuman primate", "nonhuman primate models", "novel therapeutics", "novel vaccines", "originality", "pandemic virus", "posters", "prevent", "programs", "response", "symposium", "therapy design", "tool" ], "approved": true } }, { "type": "Grant", "id": "15943", "attributes": { "award_id": "1R13OD039737-01", "title": "Annual Symposium on Nonhuman Primates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "NIH Office of the Director" ], "program_reference_codes": [], "program_officials": [ { "id": 44387, "first_name": "SIGE", "last_name": "ZOU", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-05-01", "end_date": "2028-04-30", "award_amount": 74999, "principal_investigator": { "id": 8251, "first_name": "Deborah H.", "last_name": "Fuller", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [ { "id": 44388, "first_name": "Jon E", "last_name": "Levine", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, { "id": 44389, "first_name": "Corinna Nicole", "last_name": "Ross", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "awardee_organization": { "id": 799, "ror": "", "name": "UNIVERSITY OF WISCONSIN-MADISON", "address": "", "city": "", "state": "WI", "zip": "", "country": "United States", "approved": true }, "abstract": "With this R13 application, we request funding to support, in part, the costs for planning, publicizing, and hosting the 42nd, 43rd, and 44th Annual Symposia on Nonhuman Primate Models for AIDS. For more than four decades, this symposium has served as the premier scientific forum for the exchange of information, including new research findings and scientific perspectives, among HIV/AIDS investigators whose research includes studies in nonhuman primates (NHPs). Disseminating the latest research findings in NHP models of AIDS while also facilitating discussion and exchange of information between basic scientists and clinicians remains a priority, as do focusing on emerging technologies to accelerate translation of NHP studies into the clinic and engaging a broader and more diverse group of researchers in HIV/AIDS research in NHP models. This meeting, the only one of its kind in the world, convenes an international group of scientists whose research focuses on the study of natural and experimental immunodeficiency virus infections in NHPs, as well as on the development of novel therapeutics, prophylactic vaccines for HIV, and curative approaches. Emerging topics in related infectious diseases (such as COVID-19 pathogenesis, vaccines and treatment) may also be included. The seven National Primate Research Centers (NPRCs) host this meeting in rotation, and upcoming symposia hosts will be the Wisconsin (2025), Southwest (2026), and Washington (2027) NPRCs. We plan a hybrid format with most participants attending in person and others joining online to access oral and poster sessions. The conference will begin on day 1 with registration, a keynote address by a leading HIV/AIDS researcher, and an evening reception. The following two and a half days will include scientific presentations from invited speakers and accepted oral abstracts. Each symposium scientific committee will select session topics and speakers to highlight new and cutting-edge technologies in their respective fields. Each session will open with a 30-minute talk by an invited chair. Individuals whose abstracts are accepted for oral presentations will give the remaining session talks. A poster session will occur on the evening of day 2, and there will be a banquet on the evening of day 3. As is traditional for this symposium, the Journal of Medical Primatology will publish all poster and oral abstracts in a special issue. In partnership with the HIV Vaccine Trials Network (HVTN), the NHP AIDS Symposium will also host a pre-symposium meeting for early-stage investigators (ESI). This meeting will be open to the attendees of a linked ESI Conference the HVTN sponsors. ESI attendees and mentors will focus on grant writing, budgeting, and networking, and will participate in a Q&A with NIH Program Officers. We believe bringing together researchers from a variety of diverse backgrounds will generate future collaborations and scientific advances. Knowledge shared and gained at upcoming Annual Nonhuman Primate Models for AIDS Symposia will further the continued, effective use of NHP models to maintain long term control of HIV replication in the absence of antiretroviral therapy and to design interventions to prevent or eradicate HIV infection.", "keywords": [ "2019-nCoV", "AIDS Vaccines", "Acceleration", "Acquired Immunodeficiency Syndrome", "Address", "Applications Grants", "Budgets", "COVID-19 pathogenesis", "COVID-19 treatment", "COVID-19 vaccine", "Clinic", "Collaborations", "Communicable Diseases", "Development", "Disease", "Drug Delivery Systems", "Emerging Technologies", "Epidemic", "Fees", "Fostering", "Funding", "Future", "Generations", "Grant", "HIV", "HIV Infections", "HIV Vaccine Trials Network", "HIV vaccine", "HIV/AIDS", "Health", "Human", "Hybrids", "Immune response", "Immunologist", "Individual", "International", "Intervention", "Journals", "Knowledge", "Life", "Link", "Logistics", "Medical", "Mentors", "Mission", "Monkeypox", "Oral", "Participant", "Pathogenesis", "Persons", "Preventive vaccine", "Primates", "Publishing", "Research", "Research Personnel", "Resources", "Rotation", "SIV", "Scientific Advances and Accomplishments", "Scientist", "Technology", "Testing", "Translations", "United States National Institutes of Health", "Universities", "Viral reservoir", "Virus", "Virus Diseases", "Washington", "Wisconsin", "Writing", "Zika Virus", "Zoonoses", "antiretroviral therapy", "cost", "disability", "emerging virus", "experience", "falls", "global health", "immunodeficiency", "innovation", "meetings", "neutralizing antibody", "nonhuman primate", "nonhuman primate models", "novel therapeutics", "novel vaccines", "originality", "pandemic virus", "posters", "prevent", "programs", "response", "symposium", "therapy design", "tool" ], "approved": true } } ], "meta": { "pagination": { "page": 1, "pages": 1424, "count": 14236 } } }